Market Overview

Valeant To Hold Conference Call For Investors To Provide Business Update on Tuesday, November 10, 2015 at 8:00 AM ET


Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) announced that the Company will provide a business update for investors on a conference call to be held Tuesday, November 10, 2015 at 8:00 a.m. ET.

J. Michael Pearson, Chairman and Chief Executive Officer, together with Robert Rosiello, Chief Financial Officer, Dr. Ari Kellen, Company Group Chairman, Deb Jorn, Company Group Chairman and Tanya Carro, Corporate Controller, will conduct the call.

The conference call on November 10 will consist of an overview of current plans and priorities, including the transition plan from Philidor, and an update on the Company's operations.  Immediately thereafter, there will be a question and answer segment for investors and analysts.

Valeant intends to host an Investor Day and update its annual and quarterly financial guidance prior to the end of 2015.

Conference Call Information The Company will host a conference call at 8:00 a.m. ET (5:00 a.m. PT), November 10, 2015 to provide a business update. The dial-in number to participate on this call is (877) 876-8393 confirmation code 78262163. International callers should dial (973) 200-3961, confirmation code 78262163. A replay will be available approximately two hours following the conclusion of the conference call

See full press release

Posted-In: News Guidance Management Press Releases


Related Articles (VRX)

View Comments and Join the Discussion!
Need corporate guidance data?
Click here to see licensing options.
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab's Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma

Equal Weighting Works For This Industry ETF